CoChat

BRAF and MEK inhibitors increase PD-1-positive melanoma cells leading to a potential lymphocyte-independent synergism with anti-PD-1 antibody

Open access

Published version of a preprint

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Abstract

Abstract Purpose: BRAF and MEK inhibitors (BRAF/MEKi) favor melanoma-infiltrating lymphocytes, providing the rationale for current combinatorial trials with anti–PD-1 antibody. A portion of melanoma cells may express PD-1, and anti–PD-1 antibody could have a direct antitumor effect. Here, we explore whether BRAF/MEKi modulate rates of PD-1+ melanoma cells, supporting an additional—lymphocyte-independent—basis for their therapeutic combination with anti–PD-1 antibody. Experimental Design: With data mining and flow cytometry, we assessed PD-1, PD-L1/2 expression on melanoma cell lines (CCLE, N = 61; validation cell lines, N = 7) and melanoma tumors (TCGA, N = 214). We explored in vitro how BRAF/MEKi affect rates of PD-1+, PD-L1/2+ melanoma cells, and characterized the proliferative and putative stemness features of PD-1+ melanoma cells. We tested the functional lymphocyte-independent effect of anti–PD-1 antibody alone and in combination with BRAF/MEKi in vitro and in an in vivo immunodeficient murine model. Results: PD-1 is consistently expressed on a small subset of melanoma cells, but PD-1+ cells increase to relevant rates during BRAF/MEKi treatment [7.3% (5.6–14.2) vs. 1.5% (0.7–3.2), P = 0.0156; N = 7], together with PD-L2+ melanoma cells [8.5% (0.0–63.0) vs. 1.5% (0.2–43.3), P = 0.0312; N = 7]. PD-1+ cells proliferate less than PD-1− cells (avg. 65% less; t = 7 days) and are preferentially endowed with stemness features. In vivo, the direct anti-melanoma activity of PD-1 blockage as monotherapy was negligible, but its association with BRAF/MEKi significantly delayed the development of drug resistance and tumor relapse. Conclusions: BRAF/MEKi increase the rates of PD-1+ melanoma cells that may sustain tumor relapse, providing a lymphocyte-independent rationale to explore combinatory strategies with anti–PD-1 antibody. Clin Cancer Res; 24(14); 3377–85. ©2018 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-17-1914

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 24 references

Cited by

See all 48

Metadata

Authors
Sanlorenzo, M., Vujic, I., Floris, A., Novelli, M., Gammaitoni, L., Giraudo, L., Macagno, M., Leuci, V., Rotolo, R., Donini, C., Basiricò, M., Quaglino, P., Fierro, M. T., Giordano, S., Sibilia, M., Carnevale-Schianca, F., Aglietta, M., & Sangiolo, D.
Affiliations
  • Comprehensive Cancer Center Vienna (AT)
  • Krankenanstalt Rudolfstiftung der Stadt Wien (AT)
  • University of Turin (IT)
  • Candiolo Cancer Institute (IT)
  • 6Division of Medical Oncology—Experimental Cell Therapy, Candiolo Cancer Institute, FPO—IRCCS, Candiolo, Turin, Italy.
Corresponding author
Sanlorenzo, Martina
Venue
Clinical Cancer Research
Published
2018-07-15
Volume
24
Issue
14
Pages
3377-3385
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2798102020
Cited by
47
References
23
Citations by year
2025: 6 · 2024: 7 · 2023: 5 · 2022: 8 · 2021: 8 · 2020: 5 · 2019: 5 · 2018: 3
FWCI
2.07
Type
journal article
Language
en
Open access
Locations
  • Clinical Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
  • Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
Funders
  • Ministero della Salute (Ministry of Health, Italy) (FPRC ONLUS 5x1000, GR-2011-02349197)
  • Associazione Italiana per la Ricerca sul Cancro (AIRC) (MFAG 2014 N.15731, IG20259)
  • Università degli Studi di Torino (UNITO) (Fondo Ricerca Locale 2013)
  • L'Oreal Italia (For Women in Science)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
  • Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
Keywords
BRAF/MEK inhibitors, PD-1, melanoma, anti-PD-1, PD-L1, PD-L2, tumor recurrence, drug resistance, combination therapy, melanoma cell lines, immunotherapy, tumor microenvironment, tumor cell proliferation, immunodeficient mice
MeSH terms
Antineoplastic Agents, Immunological, Animals, Cell Cycle, Disease Models, Animal, Drug Synergism, Humans, Lymphocytes, Melanoma, Mice, Transgenic, Gene Expression, Genes, Reporter, Mitogen-Activated Protein Kinase Kinases, Xenograft Model Antitumor Assays, Cell Line, Tumor, Protein Kinase Inhibitors, Proto-Oncogene Proteins B-raf, Mice, Programmed Cell Death 1 Receptor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: BRAF and MEK inhibitors increase PD-1-positive melanoma cells leading to a potential lymphocyte-independent synergism with anti-PD-1 antibody. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-17-1914
The paper
Sanlorenzo, M., Vujic, I., Floris, A., Novelli, M., Gammaitoni, L., Giraudo, L., Macagno, M., Leuci, V., Rotolo, R., Donini, C., Basiricò, M., Quaglino, P., Fierro, M. T., Giordano, S., Sibilia, M., Carnevale-Schianca, F., Aglietta, M., & Sangiolo, D. (2018). BRAF and MEK inhibitors increase PD-1-positive melanoma cells leading to a potential lymphocyte-independent synergism with anti-PD-1 antibody. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-17-1914

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.